Skip to main content

Table 2 Characteristics of patients who underwent allo-HSCT

From: PEG-aspargase and DEP regimen combination therapy for refractory Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis

Patient no. Disease status HSCT method Donor Conditioning regimen GVHD prophylaxis Adverse reactions Outcome Causes of death
1 CR HLA 5/10 related donor Sister TBI/Cy/VP-16 CsA + MTX + ATG Recurrence, acute GVHD I, sepsis Died Recurrence, sepsis
2 PR HLA5/10 related donor Brother TBI/Cy/VP-16 CsA+MTX+ATG Acute GVHD III Survival
3 CR HLA10/10 related donor Sister TBI/Cy/VP-16 CsA+MTX+ATG Pulmonary infection, acute GVHD II Survival
4 CR HLA5/10 related donor Brother TBI/Cy/VP16 CsA+MTX+ATG Recurrence, multiple organ failure Died Recurrence, multiple organ failure
5 CR HLA5/10 related donor Mother TBI/Cy/VP-16 CsA+MTX+ATG Acute GVHD I Survival
6 PR HLA5/10 related donor Mother Bu/Cy/VP-16 CsA+MTX+ATG Pulmonary infection, gastrointestinal bleeding Died Pulmonary infection, gastrointestinal bleeding
7 CR HLA5/10 related donor Sister Bu/Cy/VP-16 CsA+MTX+ATG Pulmonary infection Survival
8 CR HLA5/10 related donor Brother TBI/Cy/VP-16 CsA+MTX+ATG Acute GVHD I, gastrointestinal bleeding Survival
9 PR HLA5/10 related donor Brother TBI/Cy/VP-16 CsA+MTX+ATG Acute GVHD I Survival
10 CR HLA5/10 related donor Father TBI/Cy/VP-16 CsA+MTX+ATG Acute GVHD II, pulmonary infection Survival
11 CR HLA5/10 related donor Father TBI/Cy/VP-16 CsA+MTX+ATG Acute GVHD III, hemorrhagic cystitis Survival
12 CR HLA5/10 related donor Father TBI/Cy/VP-16 CsA+MTX+ATG Survival
13 PR HLA5/10 related donor Father TBI/Cy/VP-16 CsA+MTX+ATG Acute GVHD I, pulmonary infection Survival
  1. allo-HSCT allogeneic hematopoietic stem cell transplantation, CR complete response, PR partial response, TBI total body irradiation, Cy cyclophosphamide, VP-16 etoposide, Bu busulfan, CsA cyclosporine A, MTX methotrexate, ATG anti-thymocyte globulin, GVHD graft versus host disease